PTN Stock Price, Chart, Stats & News
Palatin Technologies, Inc. (PTN) does not currently pay a dividend.
PTN chart
Fundamentals
Gross margin | 99.25% |
Operating margin | -134.80% |
Pretax margin | -107.41% |
Net margin | -107.41% |
Effective tax rate | – |
ROA | -53.70% |
ROE | -5515.09% |
D/E | 0.03x |
Interest coverage ratio | -1552.93x |
PTN valuation
P/E | 78.36x |
P/S | 58.00x |
P/B | 1.69x |
P/CF | -1.22x |
P/FCF | -32.73x |
P/OCF | -1.22x |
PEG | 0.01x |
EV multiple | -55.83x |
About
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.
Similar securities
Based on sector and market capitalization
